MiMedx Group (NASDAQ:MDXG) Stock Rating Upgraded by StockNews.com

MiMedx Group (NASDAQ:MDXG) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $6.32 on Thursday. The firm has a market capitalization of $931.35 million, a PE ratio of 11.49 and a beta of 1.74. MiMedx Group has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The firm’s 50-day moving average is $7.40 and its two-hundred day moving average is $8.07.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.06. The company had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Analysts predict that MiMedx Group will post 0.3 EPS for the current year.

Insider Buying and Selling

In other news, CAO William Frank Iv Hulse sold 81,446 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the transaction, the chief accounting officer now directly owns 494,774 shares of the company’s stock, valued at approximately $3,859,237.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now owns 310,836 shares in the company, valued at approximately $2,452,496.04. The trade was a 1.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 144,018 shares of company stock worth $1,130,312 over the last 90 days. 1.30% of the stock is owned by insiders.

Institutional Trading of MiMedx Group

Several institutional investors have recently modified their holdings of MDXG. Invesco Ltd. grew its position in shares of MiMedx Group by 2.2% in the 4th quarter. Invesco Ltd. now owns 56,565 shares of the company’s stock valued at $544,000 after buying an additional 1,226 shares during the last quarter. OneDigital Investment Advisors LLC grew its holdings in shares of MiMedx Group by 3.9% during the first quarter. OneDigital Investment Advisors LLC now owns 55,157 shares of the company’s stock worth $419,000 after purchasing an additional 2,056 shares during the last quarter. Rhumbline Advisers increased its position in shares of MiMedx Group by 1.4% during the first quarter. Rhumbline Advisers now owns 177,156 shares of the company’s stock worth $1,346,000 after purchasing an additional 2,436 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of MiMedx Group by 77.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock valued at $63,000 after purchasing an additional 2,837 shares during the last quarter. Finally, IMG Wealth Management Inc. acquired a new stake in shares of MiMedx Group in the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.